1013 related articles for article (PubMed ID: 25964570)
41. FECAL OCCULT BLOOD: A COMPARISON OF CHEMICAL AND IMMUNOCHEMICAL TESTS.
Borges LV; Mattar R; Silva JMKD; Silva ALWD; Carrilho FJ; Hashimoto CL
Arq Gastroenterol; 2018; 55(2):128-132. PubMed ID: 30043860
[TBL] [Abstract][Full Text] [Related]
42. Fecal immunochemical testing results and characteristics of colonic lesions.
van Doorn SC; Stegeman I; Stroobants AK; Mundt MW; de Wijkerslooth TR; Fockens P; Kuipers EJ; Bossuyt PM; Dekker E
Endoscopy; 2015 Nov; 47(11):1011-7. PubMed ID: 26126163
[TBL] [Abstract][Full Text] [Related]
43. Fecal immunochemical test in colorectal cancer screening: Colonoscopy findings by different cut-off levels.
Ribbing Wilén H; Blom J; Höijer J; Hultcrantz R
J Gastroenterol Hepatol; 2019 Jan; 34(1):103-112. PubMed ID: 29968937
[TBL] [Abstract][Full Text] [Related]
44. Fecal Occult Blood Tests in Colorectal Cancer Screening: Systematic Review and Meta-analysis of Traditional and New-generation Fecal Immunochemical Tests.
Meklin J; SyrjÄnen K; Eskelinen M
Anticancer Res; 2020 Jul; 40(7):3591-3604. PubMed ID: 32620599
[TBL] [Abstract][Full Text] [Related]
45. [Diagnostic performance of quantitative fecal immunochemical test in detection of advanced colorectal neoplasia].
Lu M; Chen HD; Liu CC; Zhang YH; Wei LP; Lyu ZY; Ren JS; Shi JF; Zou SM; Li N; Dai M
Zhonghua Liu Xing Bing Xue Za Zhi; 2020 Dec; 41(12):2104-2111. PubMed ID: 33378824
[No Abstract] [Full Text] [Related]
46. Risk stratification for advanced colorectal neoplasia according to fecal hemoglobin concentration in a colorectal cancer screening program.
Auge JM; Pellise M; Escudero JM; Hernandez C; Andreu M; Grau J; Buron A; López-Cerón M; Bessa X; Serradesanferm A; Piracés M; Macià F; Guayta R; Filella X; Molina R; Jimenez W; Castells A;
Gastroenterology; 2014 Sep; 147(3):628-636.e1. PubMed ID: 24937264
[TBL] [Abstract][Full Text] [Related]
47. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening.
Park DI; Ryu S; Kim YH; Lee SH; Lee CK; Eun CS; Han DS
Am J Gastroenterol; 2010 Sep; 105(9):2017-25. PubMed ID: 20502450
[TBL] [Abstract][Full Text] [Related]
48. Quantitative immunochemical fecal occult blood testing for colorectal adenoma detection: evaluation in the target population of screening and comparison with qualitative tests.
Haug U; Hundt S; Brenner H
Am J Gastroenterol; 2010 Mar; 105(3):682-90. PubMed ID: 19953091
[TBL] [Abstract][Full Text] [Related]
49. Prospective evaluation of fecal calprotectin as a screening biomarker for colorectal neoplasia.
Limburg PJ; Devens ME; Harrington JJ; Diehl NN; Mahoney DW; Ahlquist DA
Am J Gastroenterol; 2003 Oct; 98(10):2299-305. PubMed ID: 14572583
[TBL] [Abstract][Full Text] [Related]
50. Colorectal cancer detection in an asymptomatic population: fecal immunochemical test for hemoglobin vs. fecal M2-type pyruvate kinase.
Caviglia GP; Cabianca L; Fagoonee S; Gili FM
Biochem Med (Zagreb); 2016; 26(1):114-20. PubMed ID: 26981025
[TBL] [Abstract][Full Text] [Related]
51. Cumulative evaluation of a quantitative immunochemical fecal occult blood test to determine its optimal clinical use.
Rozen P; Comaneshter D; Levi Z; Hazazi R; Vilkin A; Maoz E; Birkenfeld S; Niv Y
Cancer; 2010 May; 116(9):2115-25. PubMed ID: 20186820
[TBL] [Abstract][Full Text] [Related]
52. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection.
Hundt S; Haug U; Brenner H
Ann Intern Med; 2009 Feb; 150(3):162-9. PubMed ID: 19189905
[TBL] [Abstract][Full Text] [Related]
53. Symptom or faecal immunochemical test based referral criteria for colorectal cancer detection in symptomatic patients: a diagnostic tests study.
Herrero JM; Vega P; Salve M; Bujanda L; Cubiella J
BMC Gastroenterol; 2018 Oct; 18(1):155. PubMed ID: 30359225
[TBL] [Abstract][Full Text] [Related]
54. A prospective study of a new immunochemical fecal occult blood test in Korean patients referred for colonoscopy.
Woo HY; Mok RS; Park YN; Park DI; Sung IK; Sohn CI; Park H
Clin Biochem; 2005 Apr; 38(4):395-9. PubMed ID: 15766742
[TBL] [Abstract][Full Text] [Related]
55. Association of time to colonoscopy after a positive fecal test result and fecal hemoglobin concentration with risk of advanced colorectal neoplasia.
Kim NH; Lim JW; Kim S; Lim JY; Kim W; Park JH; Park DI; Sohn CI; Jung YS
Dig Liver Dis; 2019 Apr; 51(4):589-594. PubMed ID: 30733186
[TBL] [Abstract][Full Text] [Related]
56. An urgent referral strategy for symptomatic patients with suspected colorectal cancer based on a quantitative immunochemical faecal occult blood test.
Rodríguez-Alonso L; Rodríguez-Moranta F; Ruiz-Cerulla A; Lobatón T; Arajol C; Binefa G; Moreno V; Guardiola J
Dig Liver Dis; 2015 Sep; 47(9):797-804. PubMed ID: 26055489
[TBL] [Abstract][Full Text] [Related]
57. Colonoscopy-controlled intra-individual comparisons to screen relevant neoplasia: faecal immunochemical test vs. guaiac-based faecal occult blood test.
Oort FA; Terhaar Sive Droste JS; Van Der Hulst RW; Van Heukelem HA; Loffeld RJ; Wesdorp IC; Van Wanrooij RL; De Baaij L; Mutsaers ER; van der Reijt S; Coupe VM; Berkhof J; Bouman AA; Meijer GA; Mulder CJ
Aliment Pharmacol Ther; 2010 Feb; 31(3):432-9. PubMed ID: 19878150
[TBL] [Abstract][Full Text] [Related]
58. Diagnostic performance of flexible sigmoidoscopy combined with fecal immunochemical test in colorectal cancer screening: meta-analysis and modeling.
Niedermaier T; Weigl K; Hoffmeister M; Brenner H
Eur J Epidemiol; 2017 Jun; 32(6):481-493. PubMed ID: 28667446
[TBL] [Abstract][Full Text] [Related]
59. Lower Abnormal Fecal Immunochemical Test Cut-Off Values Improve Detection of Colorectal Cancer in System-Level Screens.
Berry E; Miller S; Koch M; Balasubramanian B; Argenbright K; Gupta S
Clin Gastroenterol Hepatol; 2020 Mar; 18(3):647-653. PubMed ID: 31085338
[TBL] [Abstract][Full Text] [Related]
60. Test performance of immunologic fecal occult blood testing and sigmoidoscopy compared with primary colonoscopy screening for colorectal advanced adenomas.
Khalid-de Bakker CA; Jonkers DM; Sanduleanu S; de Bruïne AP; Meijer GA; Janssen JB; van Engeland M; Stockbrügger RW; Masclee AA
Cancer Prev Res (Phila); 2011 Oct; 4(10):1563-71. PubMed ID: 21750209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
